Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) covers the event date of September 3, 2024. The report addresses the Company's status regarding Nasdaq listing compliance.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin data for the current period. However, it references historical financial thresholds:
- Stockholders' Equity: The Company previously failed to maintain the required minimum of $2,500,000 as of March 31, 2024.
- Market Value of Listed Securities: The Company's market value exceeded the $35 million requirement for ten consecutive trading days leading up to September 3, 2024.
Material Changes
The primary material change is the resolution of a listing deficiency. On May 20, 2024, the Company received notice of non-compliance with Nasdaq Listing Rule 5550(b)(1) due to insufficient stockholders' equity. As of September 3, 2024, Nasdaq confirmed the Company regained compliance by meeting the Market Value of Listed Securities Standard (Rule 5550(b)(2)), closing the matter.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks. The document solely confirms the restoration of good standing with the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current market capitalization to ensure it remains above the $35 million threshold.
- Review the most recent Form 10-Q or 10-K to assess the current stockholders' equity position relative to the $2.5 million minimum.
- Confirm the Company's continued compliance with other Nasdaq listing requirements not addressed in this specific 8-K.